RT Journal Article
SR Electronic
T1 Isoform-level transcriptome-wide association uncovers extensive novel genetic risk mechanisms for neuropsychiatric disorders in the human brain
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.23.22279134
DO 10.1101/2022.08.23.22279134
A1 Bhattacharya, Arjun
A1 Vo, Daniel D.
A1 Jops, Connor
A1 Kim, Minsoo
A1 Wen, Cindy
A1 Hervoso, Jonatan L.
A1 Pasaniuc, Bogdan
A1 Gandal, Michael J.
YR 2023
UL http://medrxiv.org/content/early/2023/07/06/2022.08.23.22279134.abstract
AB Integrative methods, like colocalization and transcriptome-wide association studies (TWAS), identify transcriptomic mechanisms at only a fraction of trait-associated genetic loci from genome-wide association studies (GWAS). Here, we show that a reliance on reference functional genomics panels of only total gene expression greatly contributes to this reduced discovery. This is particularly relevant for neuropsychiatric traits, as the brain expresses extensive, complex, and unique alternative splicing patterns giving rise to multiple genetically-regulated transcript-isoforms per gene. Integrating highly correlated transcript-isoform expression with GWAS requires methodological innovations.We introduce isoTWAS, a multivariate framework to integrate genetics, isoform-level expression, and phenotypic associations in a step-wise testing framework, and evaluate it using data from the Genotype-Tissue Expression (GTEx) Project, PsychENCODE Consortium, and other sources. isoTWAS shows three main advantages. First, joint, multivariate modeling of isoform expression from cis-window SNPs improves prediction by ∼1.8-2.4 fold, compared to univariate modeling. Second, compared to gene-level TWAS, these improvements in prediction lead to ∼1.9-2.5-fold increase in the number of testable genes and a median of 25-70% increase in cross-validated prediction of total gene expression, with the added ability to jointly capture expression and splicing mechanisms. In external validation, isoform-centric models predicted gene expression at percent variance explained >1% for 50% more genes than gene-centric models. Third, across 15 neuropsychiatric traits, isoTWAS increased discovery of trait associations within GWAS loci over TWAS, capturing ∼60% more unique loci and 95% of loci detected by TWAS. Results from extensive simulations showed no increase in false discovery rate and reinforce isoTWAS’s advantages in prediction and trait mapping power over TWAS, especially when genetic effects on expression vary across isoforms of the same gene. We illustrate multiple biologically-relevant isoTWAS-identified trait associations undetectable by gene-level methods, including isoforms of AKT3, CUL3, and HSPD1 with schizophrenia risk, and PCLO with multiple disorders.The isoTWAS framework addresses an unmet need to consider the transcriptome on the transcript-isoform level to increase discovery of trait associations, especially for brain-relevant traits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBP was partially supported by NIH awards R01 HG009120, R01 MH115676, R01 CA251555, R01 AI153827, R01 HG006399, R01 CA244670, and U01 HG011715. MJG was supported by SFARI Bridge to Independence Award, NIMH R01-MH121521, NIMH R01-MH123922, and NICHD-P50-HD103557.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study uses only openly available human data originally located at: GTEx genetic, transcriptomic, and covariate data were obtained through dbGAP approval at accession number phs000424.v8.p2. Linkage disequilibrium reference data from the 1000 Genomes Project were obtained at this link: https://www.internationalgenome.org/data-portal/sample. GWAS summary statistics were obtained at the following links: ADHD (https://www.med.unc.edu/pgc/download-results/), ALZ (https://ctg.cncr.nl/software/summary_statistics/), AN (http://www.med.unc.edu/pgc/results-and-downloads), ASD (https://www.med.unc.edu/pgc/download-results/), BP (https://www.med.unc.edu/pgc/download-results/), BV (https://ctg.cncr.nl/software/summary_statistics), CDG (https://www.med.unc.edu/pgc/results-and-downloads), CortTH (https://enigma.ini.usc.edu/research/download-enigma-gwas-results/), ICV (https://enigma.ini.usc.edu/research/download-enigma-gwas-results/), MDD (http://dx.doi.org/10.7488/ds/2458), NTSM (https://ctg.cncr.nl/software/summary_statistics/neuroticism_summary_statistics), OCD (https://www.med.unc.edu/pgc/download-results/), PANIC (https://www.med.unc.edu/pgc/download-results/), PTSD (https://www.med.unc.edu/pgc/results-and-downloads/), and SCZ (https://www.med.unc.edu/pgc/download-results/). The Developmental Brain RNA-seq and genotype dataset from Walker et al is available at dbGAP with accession number phs001900. The subset of Adult Brain RNA-seq and genotype data from the PsychENCODE Consortium is available at https://psychencode.synapse.org/DataAccess and from AMP-AD is available at https://adknowledgeportal.synapse.org/Data%20Access. GWAS summary statistics and accession numbers to genotype and RNA-seq data are provided in Supplemental Table S10. isoTWAS models for 48 tissues from GTEx are available at https://zenodo.org/record/8047940122, adult brain cortex from PsychENCODE and AMP-AD are available at https://zenodo.org/record/8048198123, and developmental brain cortex from Walker et al are available at https://zenodo.org/record/8048137124.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes